Skip to main content
Premium Trial:

Request an Annual Quote

NeoProteomics Receives $300K SBIR Grant to Develop Software for Personalized Medicine Tools

NEW YORK (GenomeWeb News) – NeoProteomics announced on Tuesday it has been awarded a two-year, $300,000 grant from the National Institutes of Health to develop software for commercial applications.

The Small Business Innovation Research grant will be used by the Cleveland-based protein biomarker development and software firm to develop applications for four software programs that it has licensed from Case Western Reserve University, from which NeoProteomics was spun out in 2006.

The software programs are to improve understanding of biology at a molecular level which can lead to better treatments for cancer and other diseases, the company said, adding that the SBIR grant will cover a "significant" portion of costs associated with developing the software for commercial use.

NeoProteomics plans to use the license to develop a set of products for the diagnosis of disease, prediction of disease progression, and prediction of patient response to specific treatments, Mark Chance, co-founder and chief scientific officer of the company, said in a statement.

Rod Nibbe, director of product development and senior scientist at NeoProteomics, will serve as principal investigator on the grant.

"Understanding the molecular mechanisms of complex biology inherent to many cancers and other diseases, such as Alzheimer's, and the related efforts to discover new drug targets are time consuming and expensive," Nibbe said in a statement. "Our software is intended to help academic and industrial researchers unravel the biological complexity, and by doing so lower the cost and shorten the time to development of new therapeutic agents."

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.